# SAB Biotherapeutics Inc. (SABS) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $3.72, market value $338 million.

## Valuation
- **P/E (trailing): 15.5×**. SAB Biotherapeutics Inc. trades at 15.5× trailing earnings. The Healthcare median in the September 2026 study was 28.5×.
- **Price / book: 1.4×**. The shares trade at 1.4× book value; book value is a meaningful part of the valuation.
- **Earnings yield: 6.5%**. The inverse of the P/E: 6.5% of the price is earned each year.

## Profitability
- **Return on equity: 8.8%**. 8.8% on shareholders' equity is weak; the business earns little on the capital its owners have in it.
- **Return on assets: 7.7%**. Each dollar of assets produces 7.7% of profit.

## Growth
- **Revenue growth (1 yr): -100.0%** (3-yr -100.0%/yr, 5-yr -100.0%/yr). Revenue fell 100.0% over the last year, against -100.0% a year compounded over five years: growth is accelerating.
- **EPS growth (1 yr): 78.5%**. Earnings per share rose 78.5%, faster than revenue, so margins expanded or the share count shrank.

## Financial health
- **Current ratio: 9.46** (quick 9.46). Current assets cover the next year's liabilities 9.46 times.
- **Altman Z-score: 10.45**. A Z-score of 10.45 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 3/9**. 3 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. SAB Biotherapeutics Inc. does not currently pay a dividend.

## Price and momentum
- **Total return (1 yr): 64.6%** (YTD -0.5%, 3-mo 10.1%). The shares are up 64.6% over twelve months including dividends.
- **From 52-week high: -27.8%** (101.1% above the low). Trading 28% below its 52-week high.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 49**. An RSI of 49 is neutral.
- **Beta (1 yr): 1.30** (volatility 70%). Beta of 1.30 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=SABS · Page: https://foliofundamentals.com/stocks/sabs

Not investment advice.